PEG 3500 Market Size was valued at USD 1.81 Billion in 2023. The Global PEG 3500 industry is projected to grow from USD 1.96 Billion in 2024 to USD 3.38 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.24% during the forecast period (2024 - 2032).
There are factors affecting the growth of the PEG 3500 Market are rising prevalence of colon cancer in India and other developing nations and increasing number of strategic initiatives.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The prevalence of colon cancer is increasing across India and other developing nations. In countries such as India, China, and Japan cases of colon cancer is increasing at a high rate. For instance, according to the article published by, lancet regional health Southeast Asia, colorectal cancer is the 7th most common cancer in India with 65,358 new cases in 2021. The incidence of colon cancer has been increasing worldwide and is currently 19.5 per 100,000 population globally and 15.2 per 100,000 population in India.
Moreover, rise in the number of strategic initiatives in the form of mergers, acquisitions, product approval, collaborations, and partnerships in order to gain a competitive edge and offer advanced treatment options for occasional constipation. In April 2018, US Food and Drug Administration (FDA) approved Bayer AG (Germany) MiraLAX a PEG 3350 medication drug to treat occasional constipation. Hence, increasing prevalence of colon cancer in developing nations and rising initiative strategies are driving the market growth.
The PEG 3500 Market segmentation, based on product type, includes powder and bowel preparation kit. The powder segment held the largest market share in 2021. Polyethylene glycol 3500 powder as a solution is used to treat both occasional and chronic idiopathic constipation. It is mostly prescribed once a day for up to two weeks. This powder with electrolytes is used for the short-term relief of constipation. As a result, there is a wide range of applications for treating constipation in various diseases as well prescribing with pharmaceutical drugs and giving them before medical tests to improve test results, drives segment growth.
The PEG 3500 Market data has been segmented, based on age, by pediatric, adult, and geriatric. The adult segment held the largest market share in 2021, and pediatric is the faster growing segment during the forecast period. Constipation in children and adolescents can occur for a variety of reasons. The main reasons are a lack of knowledge about proper diets for pediatrics and children, as well as mental health. PEG 3500 can be used in pediatric patients without electrolytes; it is a safe, effective, and well-tolerated option for the treatment of constipation in children. Hence, PEG 3500 is a safe treatment for constipation, and further, the demand for PEG 3500 will be high among the pediatric population owing to the high colorectal cancer prevalence, which further fuels age segment growth.
The PEG 3500 Market data has been segmented, based on application, by constipation, medical tests, and surgery. The constipation segment held the largest market share in 2021, and medical tests is the faster growing segment during the forecast period. Constipation is the most common gastrointestinal problem. The increasing incidence of constipation among the worldwide population further increases the demand for PEG 3500 powder. Constipation can also occur in patients who suffer from a stroke. According to the study, up to 85% of stroke patients may experience constipation. In October 2021, the World Health Organization estimated that 70% of strokes occur in low- and middle-income countries. As a result of the rising prevalence of constipation in the developing regions due to unhealthy lifestyles and the fact that patients with chronic diseases experience constipation, physicians & pharmacists are increasingly prescribing PEG 3500, bolstering segment growth.
Figure 2: PEG 3500 Market, by Application, 2021 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Based on distribution channel, the global PEG 3500 industry has been segmented into the online pharmacy and offline pharmacy. The offline segment held the largest market share in 2021. Offline pharmacies will have lucrative growth opportunities in the coming years owing to several factors. The factors include rising surgical procedures associated with the colon and rectum and other colon-related diseases that require medical tests. Offline pharmacies include hospital pharmacies, retail pharmacies, and wholesale pharmacies. As per the research, PEG 3500 is more likely to be in demand in hospital pharmacies and near the pharmacies of Ambulatory Surgical Centres (ASC). This is due to the increasing number of colorectal surgery procedures. Hence, the increasing number of surgical procedures is due to the increase in colon and rectal cancer further fueling segment growth.
By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America PEG 3500 market accounted for the largest market share in 2021, due to the rising prevalence of colorectal cancer and other diseases such as diabetes, cancer, and neurological disorders increases the demand for PEG 3500, driving the region's growth.
Further, the major countries studied are: The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: PEG 3500 MARKET BY REGION 2021 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe PEG 3500 market accounts for the second-largest market share owing to the increasing adoption of a sedentary lifestyle further increases the chance of colon cancer. Colorectal cancer is the most common form of cancer in Europe. As per the World Cancer Research Fund International, Hungary had the highest colorectal cancer number, followed by Slovakia in 2020 globally. Furthermore, the Germany PEG 3500 market held the largest market share 2021, and is projected to be the fastest growing during the forecast period.
The Asia-Pacific PEG 3500 market is expected to grow at a significant share from 2024 to 2032 rising geriatric population, adoption of sedentary lifestyles and physical inactivity, and the rising prevalence of colorectal cancer. The prevalence of constipation among the geriatric population is high and chronic. In 2020, according to the World Economic Forum, China, India, and Japan had the oldest populations globally. Furthermore, it has been estimated that by 2050, one in four older people will be living in the Asia-Pacific region. Moreover, China PEG 3500 market held the largest market share, and India PEG 3500 market is projected to be the fastest growing market in the Asia-Pacific region.
Major market players are spending a lot of money on R&D to increase their product lines, which will help the PEG 3500 market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the PEG 3500 industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
Pendopharm (Canada) manufactures and distributes pharmaceutical products. The Company offers licensing, partnering, developing, and marketing specialty prescription medicines, as well as consumer healthcare products. Pendopharm serves customers in Canada. In March 2021, the company launched Colyte Polyethylene Glycol 3350 and Electrolytes for Oral Solution is used to cleanse the colon (bowel) before certain medical tests (e.g., colonoscopy, barium enema X-ray exam) or colon surgery.
March 2021: Pendopharm (Canada) launched Colyte Polyethylene Glycol 3350 and Electrolytes for Oral Solution is used to cleanse the colon (bowel) before certain medical tests (e.g., colonoscopy, barium enema X-ray exam) or colon surgery.
April 2018: The US Food and Drug Administration has approved Bayer AF (Germany) MiraLAX a Polyethylene Glycol 3350 medication drug to treat occasional constipation.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 1.81 billion |
| Market Size 2024 | USD 1.96 billion |
| Market Size 2032 | USD 3.38 billion |
| Compound Annual Growth Rate (CAGR) | 6.24% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2018 & 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Age, Application, Distribution Channel, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Pendopharm (Canada), Bayer AG (Germany), Merck KGaA (US), Lupin Pharmaceuticals, Inc. (India), Breckenridge Pharmaceutical, Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), LGM Pharma (US), McKesson Corporation (US), Sisco Research Laboratories Pvt. Ltd. (India), BASF SE (Germany), and others |
| Key Market Opportunities | Entering developing markets |
| Key Market Drivers | Rising prevalence of colon cancer in India and other developing nations Increasing number of strategic initiatives |
PEG 3500 Market Highlights:
Frequently Asked Questions (FAQ) :
The PEG 3500 Market is anticipated to reach 3.38 billion at a CAGR of 6.24% during the forecast period of 2024-2032.
The US is expected to hold an 91.67% share of the global market for PEG 3500 market during the forecast period of 2024-2032.
The PEG 3500 market is expected to grow at a 6.24% CAGR during the forecast period from 2024 to 2032.
The North America region market held the largest market share in PEG 3500 market.
The key players include Pendopharm (Canada), Bayer AG (Germany), Merck KGaA (US), Lupin Pharmaceuticals, Inc. (India), Breckenridge Pharmaceutical, Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), LGM Pharma (US), McKesson Corporation (US), Sisco Research Laboratories Pvt. Ltd. (India), BASF SE (Germany), and others.
The powder product type led the PEG 3500 market.
Constipation application segment had the largest market in 2021, with market share 76.68%.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
